Skip to main content
Skip to header right navigation
Skip to site footer

Endogenex

Bringing New Energy to the Treatment of Type 2 Diabetes

T2D
Technology
Patients
Clinical Providers
- Study Team
About Us
- News
- Contact
ReCET Study

Jennifer Strumbel

Endogenex

Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approval

* Caution: Exclusively a clinical investigational device. Limited by federal (or United States or similar) law to investigational use. Not for sale in any geography.

Please refer to your physician for additional information on the pulsENDO procedure, pulsENDO system, and related risks.

Endogenex, Inc.
13755 1st Avenue North #100
Plymouth, MN 55441
+1 763-251-6820
info@endogenex.com

Endogenex and pulsENDO are registered trademarks of Endogenex, Inc. in the United States and other countries. Copyright © 2026 Endogenex, Inc. All rights reserved.

LinkedIn
X
Vimeo